Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
poly-ICLC + peptide-pulsed dendritic cell vaccine
- Development stage
- Unknown
- Lead developer
- Medical University of South Carolina
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics, Peptides
- Administration
- Intradermal, Intramuscular
01
Overview
This investigational cancer immunotherapy, developed at the Medical University of South Carolina, consists of autologous dendritic cells pulsed with three tumor-associated antigen peptides (hTERT, CEA, and survivin) and administered alongside the TLR3 agonist adjuvant Poly-ICLC (Hiltonol). The vaccine is designed to induce and expand tumor-specific CD8+ T-cell responses in HLA-A2+ patients. It has been primarily evaluated for the treatment of metastatic or locally advanced unresectable pancreatic adenocarcinoma, where it demonstrated safety and the ability to elicit measurable immune responses in early-phase clinical testing.
- Other names
- Poly-ICLC and Peptide-pulsed DC VaccinehTERT/CEA/survivin peptide-pulsed dendritic cell vaccineHiltonol and peptide-pulsed dendritic cell vaccine
02
Targets
T-cell receptor recognizing survivin SRV.A2/HLA-A2 peptide-MHC complexTLR3 (Toll-like receptor 3)
Beyond the preview
Go deeper on poly-ICLC + peptide-pulsed dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on poly-ICLC + peptide-pulsed dendritic cell vaccine.